Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab and azathioprine versus azathioprine in moderate to severe active ulcerative colitis (Part 1)
2006-002670-22Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Jun 2007
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in autoimmune colitis comparing Infliximab + azathioprine, Infliximab monotherapy and Azathioprine monotherapy (3 arms). Primary endpoints: Part 1 corticosteroid-free clinical remission at Week 16 and Part 2 average remission rate over duration of treatment. Started Jun 2007; status: terminated.
02
Drugs
infliximabazathioprine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2006-002670-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002670-22.